Furthermore, the combination of systemic and transhepatic arterial chemotherapy was not recommended for HCC following potentially curative treatment, therefore, postoperative IFN-α therapy may be beneficial for HBV-associated HCC patients (78,79). This evidence concerns the gene IFNA2 and hepatocellular carcinoma.